Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck & Co’s TROP2 Partner Trumpets Phase III Success In TNBC

Kelun Planning China Filings

Aug 14 2023

• By Kevin Grogan

• Source: Shutterstock

Related Content

Five Key Takeaways From Merck’s Q2 Earnings Release

Aug 01 2023

Gilead’s Trodelvy May Have Safety Edge Due To Lack Of Concerning Lung Toxicity

Aug 04 2023

AstraZeneca’s Dato-DXd Falls Short Of Great Expectations In Lung Cancer Study

Jul 03 2023

Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs

Dec 22 2022

Related Companies

Merck & Co., Inc.

Sichuan Kelun Pharmaceutical Co Ltd.

Gilead Sciences, Inc.

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Additional Topics

Clinical Trials Companies Research & Development Strategy Cancer BioPharmaceutical

More from Anticancer

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window